California Launches Portal for Reporting Alleged Misconduct by Federal Immigration Agents 
Apple Alerts EU Regulators That Apple Ads and Maps Meet DMA Gatekeeper Thresholds 
Taiwan Signals Openness to Renew Ties with Honduras as Election Unfolds 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Minneapolis Leaders Push Back as Trump Escalates Rhetoric Against Somali Community 
Trump’s Name Appears on U.S. Institute of Peace Ahead of Rwanda–Congo Deal Signing 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Maduro Confirms “Respectful” Call With Trump, Signals Openness to Diplomatic Dialogue 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
New Orleans Immigration Crackdown Sparks Fear as Federal Arrests Intensify 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
U.S. President Donald Trump has requested a safety review of abortion pills, according to Health and Human Services Secretary Robert F. Kennedy Jr. in an interview with Fox News on Thursday. The move signals a potential policy shift as Trump evaluates whether to tighten regulations on the medication.
Kennedy Jr. stated that the administration aims to ensure public safety by thoroughly assessing the risks and benefits of abortion pills. He emphasized that no decision has been made regarding restrictions and that the findings of the study will guide future policies.
The announcement has sparked strong reactions from advocacy groups on both sides of the abortion debate. Pro-life organizations support the study, arguing that stricter rules could protect women's health. Meanwhile, pro-choice advocates criticize the move, expressing concerns that it could limit access to safe reproductive healthcare.
This development comes as abortion rights remain a highly contested topic in the U.S., with recent legal battles over reproductive laws drawing national attention. The outcome of the study could significantly impact abortion pill access and influence ongoing state-level debates.
As the administration reviews the data, both supporters and opponents are closely monitoring the situation. Kennedy Jr. assured that transparency and scientific evidence would be at the forefront of any policy changes.
The decision on whether to impose new restrictions will follow the completion of the study, though no timeline has been provided. The White House has yet to release further comments.
This review highlights the ongoing political and social tensions surrounding reproductive rights, with potential implications for healthcare policies ahead of the upcoming election cycle.
